Conditions

FLUTICASONE PROPIONATE AND SALMETEROL

Drug approval information sourced from the FDA and the PBS. Updated nightly from public government registries. Not medical advice.

Access in Australia

  • This medicine is listed on the PBS, first listed 1 August 2000, according to the Pharmaceutical Benefits Scheme. Your doctor can advise whether a PBS-subsidised option is appropriate for you.
  • TGA registration data for this medicine is not yet available on Voxsanity.
Updated regularly from public government registries

How it works: Adrenergic beta2-Agonists

Drug class: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics

Approval status

FDA Approved

17 December 2020
US Food and Drug Administration

PBS Listed

1 August 2000
Pharmaceutical Benefits Scheme (Australia)

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Regulatory approval does not guarantee this drug is available to you. Availability in Australia depends on PBS listing status, your specific diagnosis, your doctor's assessment, and other clinical factors.

Accessing this drug in Australia

This drug is listed on the PBS. Available on a standard prescription from your GP.

This information is drawn from publicly available PBS records. It is not medical advice. Consult your doctor about access options for your specific situation.

Approval data sourced from openFDA (CC0 licence), and the PBS schedule. Updated nightly. This page does not constitute medical advice. Drug availability and PBS listing status may change. Verify current availability and PBS coverage with your doctor or pharmacist.